CASE STUDIES

From strategy to execution—measured in results that move therapies from pipeline to patients

Close-up of a nautilus shell revealing its golden spiral chambers.

Start-up through Acquisition

Work was proudly recognized in acquisition press release, highlighting a 29% reduction in data collection costs. The asset achieved 63% clinical remission vs. 21% placebo, contributing to a $7.1B acquisition.



Full-time clinical operations team members hired with 100% retention

25

Streamlined CRO partnerships during Ph2


20+ Countries/80+ Sites

IBD-specific staff trained with tailored programs

92M


$50M

Saved through vendor negotiations


Company acquired by Roche

$7.1B


Overview of a woman in a cream blouse and burgundy pants typing on a laptop while seated in a green armchair.

Pre-IPO Biotech through Ph3 Ready

Led clinical operations from the ground up, managing a $100M+ portfolio, building a high performing team, and ensuring trials not only ran faster but smarter. That foundation helped the company raise $150M and go public during a volatile market.



Built and managed in-house clinical operations team as first clinical hire

20+


Faster execution of clinical trial timelines, even during COVID

22%

Avg. 1.5 years in role

92% Team Retention



Improvement in screen failure rate

17%


5 major milestones completed on time and under budget

5